HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma.

Abstract
Although sublingual immunotherapy (SLIT) is accepted to be a viable alternative of specific-allergen immunotherapy, the efficacy of long-term SLIT in asthmatic children is not well established. The efficacy of 3 yr of SLIT in addition to pharmacotherapy was compared with pharmacotherapy alone in a prospective, open, parallel-group, controlled study. Children with asthma aged 4-16 yr, sensitive to house dust mite (HDM) were followed up for a run-in period of 1 yr and then grouped as those who would receive SLIT + pharmacotherapy (n = 62) or pharmacotherapy alone (n = 28). All patients were evaluated based on symptom-medication scores and lung function tests every 3 months, as well as skin-prick test and serum total immunoglobulin E (IgE) levels annually for 3 yr. Children in the SLIT + pharmacotherapy group demonstrated significantly lower mean daily dose and annual duration of inhaled corticosteroid (ICS) usage when compared with controls. At the end of the 3 yr, within-group comparisons revealed statistically significant decreases in the dose and duration of ICS only in the SLIT group. Furthermore, 52.4% of subjects in the SLIT + pharmacotherapy group were able to discontinue ICS treatment for at least 6 months, which was only 9.1% for the pharmacotherapy group. Three years of SLIT as an adjunct to pharmacotherapy resulted in reduction of both the duration and dose of ICSs and successful discontinuation of ICSs along with improvement in lung functions in HDM-allergic children with asthma.
AuthorsCevdet Ozdemir, Didem Yazi, Izlem Gocmen, Ozlem Yesil, Metin Aydogan, Aida Semic-Jusufagic, Nerin N Bahceciler, Isil B Barlan
JournalPediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology (Pediatr Allergy Immunol) Vol. 18 Issue 6 Pg. 508-15 (Sep 2007) ISSN: 0905-6157 [Print] England
PMID17680909 (Publication Type: Controlled Clinical Trial, Journal Article)
Chemical References
  • Adrenal Cortex Hormones
  • Anti-Asthmatic Agents
  • Antigens, Dermatophagoides
  • Immunoglobulin E
  • Budesonide
Topics
  • Administration, Inhalation
  • Administration, Sublingual
  • Adolescent
  • Adrenal Cortex Hormones (administration & dosage, therapeutic use)
  • Animals
  • Anti-Asthmatic Agents (administration & dosage, therapeutic use)
  • Antigens, Dermatophagoides (administration & dosage)
  • Asthma (drug therapy, immunology, therapy)
  • Budesonide (administration & dosage, therapeutic use)
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Desensitization, Immunologic (methods)
  • Female
  • Humans
  • Hypersensitivity (drug therapy, immunology, therapy)
  • Immunoglobulin E (blood)
  • Infant
  • Male
  • Prospective Studies
  • Pyroglyphidae (immunology)
  • Respiratory Function Tests
  • Skin Tests
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: